Supplementary Table 1. Baseline characteristics of the genotyped and non-genotyped patients.

Supplementary Figure 1. Kaplan-Meier curves for the primary (A) and secondary (B) efficacy endpoints for loss-of-function allele carriers versus non-carriers in the clopidogrel and placebo treated patients and Kaplan-Meier curves for GUSTO severe and moderate bleeding (C) and all GUSTO bleeding (D) for loss-of-function allele carriers versus non-carriers in the clopidogrel and placebo treated patients. Analyses are for patients of European, Asian, and African ancestry.

Supplementary Figure 2. Kaplan-Meier curves for the primary (A) and secondary (B) efficacy endpoints for gain-of-function allele carriers versus non-carriers in the clopidogrel and placebo treated patients and Kaplan-Meier curves for GUSTO severe and moderate bleeding (C) and all GUSTO bleeding (D) for gain-of-function allele carriers versus non-carriers in the clopidogrel and placebo treated patients. Analyses are for patients of European, Asian, and African ancestry.

Supplementary Figure 3. Results in the CAPRIE-like cohort. Kaplan-Meier curves for the primary (A) and secondary (B) efficacy endpoints for loss-of-function allele carriers versus non-carriers in the clopidogrel and placebo treated patients and Kaplan-Meier curves for GUSTO severe and moderate bleeding (C) and all GUSTO bleeding (D) for loss-of-function allele carriers versus non-carriers in the clopidogrel and placebo treated patients. Analyses are for patients of European ancestry.

Supplementary Figure 4. Results in the CAPRIE-like cohort. Kaplan-Meier curves for the primary (A) and secondary (B) efficacy endpoints for gain-of-function allele carriers versus non-carriers in the clopidogrel and placebo treated patients and Kaplan-Meier curves for GUSTO severe and moderate bleeding (C) and all GUSTO bleeding (D) for gain-of-function allele carriers versus non-carriers in the clopidogrel and placebo treated patients. Analyses are for patients of European ancestry.

Supplementary Figure 5. Results in the cohort with prior PCI. Hazard ratios for clopidogrel versus placebo for efficacy and bleeding endpoints by carrier status for loss-of-function and gain-of-function alleles. Analyses are for patients of European ancestry and are adjusted for age and sex.
Supplementary Figure 1
Supplementary Figure 2
Supplementary Figure 3

A  Freedom from First Primary Composite Endpoint According to Loss−of−Function Allele Carrier Status

B  Freedom from Second Primary Composite Endpoint According to Loss−of−Function Allele Carrier Status

C  Freedom from Major Bleeding According to Loss−of−Function Allele Carrier Status

D  Freedom from All Bleeds According to Loss−of−Function Allele Carrier Status

No. at Risk

Days After Randomization

Carriers Clopidogrel
Noncarriers Clopidogrel
Carriers Placebo
Noncarriers Placebo

Carriers/Clopidogrel (N events=31)
Noncarriers/Clopidogrel (N events=58)
Carriers/Placebo (N events=23)
Noncarriers/Placebo (N events=67)

No. at Risk

Days After Randomization

Carriers Clopidogrel
Noncarriers Clopidogrel
Carriers Placebo
Noncarriers Placebo

Carriers/Clopidogrel (N events=71)
Noncarriers/Clopidogrel (N events=158)
Carriers/Placebo (N events=69)
Noncarriers/Placebo (N events=176)

No. at Risk

Days After Randomization

Carriers Clopidogrel
Noncarriers Clopidogrel
Carriers Placebo
Noncarriers Placebo

Carriers/Clopidogrel (N events=21)
Noncarriers/Clopidogrel (N events=32)
Carriers/Placebo (N events=4)
Noncarriers/Placebo (N events=30)

No. at Risk

Days After Randomization

Carriers Clopidogrel
Noncarriers Clopidogrel
Carriers Placebo
Noncarriers Placebo

Carriers/Clopidogrel (N events=128)
Noncarriers/Clopidogrel (N events=383)
Carriers/Placebo (N events=78)
Noncarriers/Placebo (N events=206)

Log−rank test P = 0.143
within clopidogrel treated participants

Log−rank test P = 0.25
within clopidogrel treated participants

Log−rank test P = 0.056
within clopidogrel treated participants

Log−rank test P = 0.05
within clopidogrel treated participants
Supplementary Figure 4
<table>
<thead>
<tr>
<th>Carrier Type</th>
<th>Outcome</th>
<th>Carrier Status</th>
<th>Placebo Event Rate</th>
<th>Clopidogrel Event Rate</th>
<th>Hazard Ratio (95% CI)</th>
<th>Heterogeneity P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loss−of−Function</td>
<td>First Primary Composite</td>
<td>Carriers</td>
<td>5.4% (10/186)</td>
<td>3.4% (6/175)</td>
<td>0.70 (0.25–1.94)</td>
<td>0.629</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Noncarriers</td>
<td>5.5% (23/421)</td>
<td>4.7% (21/444)</td>
<td>0.86 (0.48–1.56)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total</td>
<td>5.4% (33/607)</td>
<td>4.4% (27/619)</td>
<td>0.81 (0.49–1.34)</td>
<td>0.629</td>
</tr>
<tr>
<td></td>
<td>Second Primary Composite</td>
<td>Carriers</td>
<td>22.0% (41/186)</td>
<td>17.7% (31/175)</td>
<td>0.79 (0.49–1.25)</td>
<td>0.702</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Noncarriers</td>
<td>23.8% (100/421)</td>
<td>21.2% (94/444)</td>
<td>0.87 (0.65–1.15)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total</td>
<td>23.2% (141/607)</td>
<td>20.2% (125/619)</td>
<td>0.84 (0.66–1.07)</td>
<td>0.702</td>
</tr>
<tr>
<td></td>
<td>Major Bleed</td>
<td>Carriers</td>
<td>1.1% (2/186)</td>
<td>4.0% (7/175)</td>
<td>3.74 (0.77–18.05)</td>
<td>0.081</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Noncarriers</td>
<td>2.6% (11/421)</td>
<td>2.3% (10/444)</td>
<td>0.87 (0.37–2.05)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total</td>
<td>2.1% (13/607)</td>
<td>2.7% (17/619)</td>
<td>1.30 (0.63–2.68)</td>
<td>0.081</td>
</tr>
<tr>
<td></td>
<td>All Bleed</td>
<td>Carriers</td>
<td>24.2% (45/186)</td>
<td>40.6% (71/175)</td>
<td>1.91 (1.31–2.77)</td>
<td>0.429</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Noncarriers</td>
<td>23.8% (100/421)</td>
<td>44.8% (199/444)</td>
<td>2.19 (1.72–2.79)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total</td>
<td>23.9% (145/607)</td>
<td>43.6% (270/619)</td>
<td>2.11 (1.72–2.58)</td>
<td>0.429</td>
</tr>
<tr>
<td>Gain−of−Function</td>
<td>First Primary Composite</td>
<td>Carriers</td>
<td>5.1% (12/236)</td>
<td>3.0% (7/231)</td>
<td>0.60 (0.24–1.53)</td>
<td>0.495</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Noncarriers</td>
<td>5.7% (21/371)</td>
<td>5.2% (20/388)</td>
<td>0.93 (0.50–1.71)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total</td>
<td>5.4% (33/607)</td>
<td>4.4% (27/619)</td>
<td>0.81 (0.49–1.34)</td>
<td>0.495</td>
</tr>
<tr>
<td></td>
<td>Second Primary Composite</td>
<td>Carriers</td>
<td>20.8% (49/236)</td>
<td>20.3% (47/231)</td>
<td>0.96 (0.65–1.44)</td>
<td>0.450</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Noncarriers</td>
<td>24.8% (92/371)</td>
<td>20.1% (78/388)</td>
<td>0.78 (0.58–1.05)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total</td>
<td>23.2% (141/607)</td>
<td>20.2% (125/619)</td>
<td>0.84 (0.66–1.07)</td>
<td>0.450</td>
</tr>
<tr>
<td></td>
<td>Major Bleed</td>
<td>Carriers</td>
<td>2.1% (5/236)</td>
<td>2.6% (6/231)</td>
<td>1.20 (0.37–3.94)</td>
<td>0.429</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Noncarriers</td>
<td>2.2% (8/371)</td>
<td>2.8% (11/388)</td>
<td>1.38 (0.56–3.44)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total</td>
<td>2.1% (13/607)</td>
<td>2.7% (17/619)</td>
<td>1.30 (0.63–2.68)</td>
<td>0.429</td>
</tr>
<tr>
<td></td>
<td>All Bleed</td>
<td>Carriers</td>
<td>24.2% (57/236)</td>
<td>45.5% (105/231)</td>
<td>2.22 (1.61–3.06)</td>
<td>0.902</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Noncarriers</td>
<td>23.7% (88/371)</td>
<td>42.5% (165/388)</td>
<td>2.04 (1.58–2.65)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total</td>
<td>23.9% (145/607)</td>
<td>43.6% (270/619)</td>
<td>2.11 (1.72–2.58)</td>
<td>0.902</td>
</tr>
</tbody>
</table>

Supplementary Figure 5